LivaNova PLC (NASDAQ:LIVN) Shares Acquired by Fuller & Thaler Asset Management Inc.

Fuller & Thaler Asset Management Inc. grew its stake in LivaNova PLC (NASDAQ:LIVN - Free Report) by 8.0% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 620,111 shares of the company's stock after purchasing an additional 45,830 shares during the period. Fuller & Thaler Asset Management Inc. owned approximately 1.14% of LivaNova worth $28,717,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Russell Investments Group Ltd. increased its stake in LivaNova by 17.1% during the 4th quarter. Russell Investments Group Ltd. now owns 1,502 shares of the company's stock worth $70,000 after buying an additional 219 shares during the period. Sterling Capital Management LLC grew its stake in LivaNova by 800.6% during the 4th quarter. Sterling Capital Management LLC now owns 1,621 shares of the company's stock worth $75,000 after purchasing an additional 1,441 shares in the last quarter. Central Pacific Bank Trust Division raised its position in LivaNova by 21.2% in the 4th quarter. Central Pacific Bank Trust Division now owns 4,117 shares of the company's stock valued at $191,000 after purchasing an additional 720 shares in the last quarter. Vestcor Inc acquired a new position in shares of LivaNova during the fourth quarter worth about $204,000. Finally, Optimize Financial Inc purchased a new stake in shares of LivaNova in the 4th quarter valued at approximately $208,000. Hedge funds and other institutional investors own 97.64% of the company's stock.

LivaNova Price Performance

Shares of NASDAQ LIVN traded down $0.48 during trading on Wednesday, reaching $37.18. The company had a trading volume of 234,926 shares, compared to its average volume of 620,756. LivaNova PLC has a twelve month low of $32.48 and a twelve month high of $64.48. The stock has a 50-day moving average price of $38.54 and a two-hundred day moving average price of $45.93. The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46. The stock has a market capitalization of $2.02 billion, a PE ratio of 88.52 and a beta of 0.90.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on LIVN. StockNews.com upgraded LivaNova from a "buy" rating to a "strong-buy" rating in a research note on Tuesday, March 25th. The Goldman Sachs Group dropped their price target on LivaNova from $64.00 to $55.00 and set a "buy" rating on the stock in a research note on Monday, March 3rd. Needham & Company LLC reissued a "buy" rating and set a $64.00 price objective on shares of LivaNova in a research report on Monday, March 17th. Mizuho lowered their price target on LivaNova from $70.00 to $60.00 and set an "outperform" rating on the stock in a report on Wednesday, February 26th. Finally, Barclays reduced their price objective on LivaNova from $58.00 to $56.00 and set an "equal weight" rating for the company in a research note on Friday, March 7th. Two analysts have rated the stock with a hold rating, five have assigned a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, LivaNova presently has an average rating of "Buy" and an average target price of $61.17.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.